Friday, October 23, 2015


Hall A

Industry Symposium
Controversies in bone health 

Supported by Amgen Oncology

Chairpersons: Richard De Boer, Australia
Michael Green, Australia
08:30 The science behind RANK Ligand and its potential impact in breast cancer
Geoff Lindeman, Australia
08:50 Bone targeted agents in metastatic breast cancer: Do bisphosphonates still have a role?
Jodi Lynch, Australia
09:10 Is there a role for radical treatment for isolated or asymptomatic bone metastases?
Abe Recht, USA
09:30 Denosumab: Are hypocalcaemia and ONJ inevitable?
Richard de Boer, Australia/ Tracey Huntley, Australia 
09:50 Discussion



Hall A

Industry Symposium
Controversies in HER2-positive disease

Supported by Roche Oncology


Chairpersons: Nicole McCarthy, Australia
Javier Cortes, Spain
11:30 How should TILS influence the management of the HER2-positive patient?
Sherene Loi, Australia
11:50 T-DM1 and Pertuzumab: Where do they fit?
Javier Cortes, Spain
12:10 Discussion
12:25-13:00 Debate: Should all early stage HER2-positive patients receive adjuvant anti-HER therapy?
12:25 Yes: Edith Perez, USA
12:35 No:  Arlene Chan, Australia
12:45 Discussion




Saturday, October 24, 2015



Hall A


Industry Breakfast Symposium
IORT for early breast cancer: From clinical trials to clinical reality


Chairperson: Christobel Saunders, Australia
07:15 ZEISS INTRABEAM System: A radiotherapy platform, TARGIT study update and new therapy options
Robert M. Hermann, Germany
07:30 General principles of IORT and why we embarked on it
Maria Pearse, New Zealand 
07:45 TARGIT Trial results
Max Bulsara, Australia
08:00 Practicalities of setting up IORT
Erica Whineray Kelly, New Zealand
08:15 Discussion

 Breakfast will be served prior to the session



Hall A

Industry Symposium
Management of endocrine resistance

Supported by Novartis Oncology


Chairpersons: Richard De Boer, Australia
Louis Chow, Hong Kong
11:30 Endocrine resistance: The science behind the studies
Stephen R.D. Johnston, UK
11:50 Current strategies: Their advantages and practical limitations
Patient selection
Toxicity management
Arlene Chan, Australia
12:10-13:00 Debate: Targeted therapies and endocrine treatments should be combined upfront before endocrine resistance can develop
12:10 Yes: Javier Cortes, Spain
12:20 No:  Stephen R.D. Johnston, UK
12:30 Discussion